文献速递胸部肿瘤

帕博利珠单抗对比化疗在PD-L1阳性晚期NSCLC的健康相关生活质量:KEYNOTE-024研究

Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial.
PubMed 文献 · Lancet Oncol · 2017-11-09

KEYNOTE-024是一项国际多中心随机开放标签3期试验,在PD-L1肿瘤比例评分≥50%的初治晚期NSCLC患者中比较帕博利珠单抗与铂类化疗。

要点

  • 帕博利珠单抗较化疗显著改善PD-L1阳性晚期NSCLC患者第15周整体健康状况/生活质量。
  • 帕博利珠单抗可能成为PD-L1高表达晚期NSCLC新的一线标准治疗。

核心结论

  • 与化疗相比,帕博利珠单抗改善或维持了PD-L1阳性晚期NSCLC患者的健康相关生活质量。
  • 帕博利珠单抗可能代表PD-L1表达晚期NSCLC新的一线标准治疗。

研究设计与样本

  • 多中心、国际、随机、开放标签3期试验,在16个国家102个中心招募初治IV期NSCLC患者。
  • 305例患者随机1:1接受帕博利珠单抗200 mg每3周(35周期)或研究者选择的铂类双药化疗(4-6周期)。
  • PRO分析纳入至少接受一剂研究治疗且至少一个时间点完成至少一份PRO问卷的患者,共299例。

主要发现

  • QLQ-LC13复合终点(咳嗽、胸痛、呼吸困难)恶化:帕博利珠单抗组46/151例(31%),化疗组58/148例(39%)。
  • PRO依从性在基线时两组均大于90%,第15周时约为80%。

临床怎么用

  • 对于PD-L1肿瘤比例评分≥50%的初治晚期NSCLC患者,帕博利珠单抗在改善生存的同时可改善或维持健康相关生活质量。
  • 临床决策中可将患者报告结局作为支持帕博利珠单抗一线治疗的依据之一。

局限性

  • PRO分析为预设探索性终点,统计检验为名义P值,未进行多重性校正。
  • 开放标签设计可能影响患者报告结局的评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In the phase 3 KEYNOTE-024 trial, treatment with pembrolizumab conferred longer progression-free survival than did platinum-based therapy in patients with treatment-naive, advanced non-small-cell lung cancer (NSCLC) with a programmed cell death-ligand 1 (PD-L1) tumour proportion score of 50% or greater (PD-L1-positive). Here we report the prespecified exploratory endpoint of pembrolizumab versus chemotherapy on patient-reported outcomes (PROs). METHODS: In this multicentre, international, randomised, open-label, phase 3 trial, we recruited patients with treatment-naive, stage IV NSCLC in 102 sites in 16 countries. Eligible patients had measurable disease (per RECIST version 1.1) and an Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1. Patients were randomly assigned (1:1) via an interactive voice response system and integrated web response system to receive either pembrolizumab 200 mg every 3 weeks (35 cycles) or investigator-choice platinum-doublet chemotherapy (4-6 cycles or until documented disease progression or unacceptable toxicity). Randomisation was stratified according to geography, ECOG performance status, and histology. PROs were assessed at day 1 of cycles 1-3, every 9 weeks thereafter, at the treatment discontinuation visit, and at the 30-day safety assessment visit using the European Organisation for the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 items (QLQ-C30), the EORTC Quality of Life Questionnaire Lung Cancer 13 items (QLQ-LC13), and the European Quality of Life 5 Dimensions-3 Level (EQ-5D-3L) questionnaire. The key exploratory PRO endpoints (analysed for all patients who received at least one dose of study treatment and completed at least one PRO instrument at at least one timepoint) were baseline-to-week-15 change in the QLQ-C30 global health status (GHS)/quality-of-life (QOL) score and time to deterioration of the composite of cough, chest pain, and dyspnoea in the QLQ-LC13. This study is registered with ClinicalTrials.gov, number NCT02142738, and is ongoing but no longer enrolling patients. FINDINGS: Between Sept 19, 2014, and Oct 29, 2015, 305 patients were randomly assigned to pembrolizumab (n=154) or chemotherapy (n=151). Three patients in each group did not complete any PRO instruments at any timepoints, and so 299 patients were included in the full analysis set. Of these patients, one in each group did not complete any PRO instruments before week 15, and so were not included in analyses of change from baseline to week 15. PRO compliance was greater than 90% at baseline and approximately 80% at week 15 for both groups. Least-squares mean baseline-to-week-15 change in QLQ-C30 GHS/QOL score was 6·9 (95% CI 3·3 to 10·6) for pembrolizumab and -0·9 (-4·8 to 3·0) for chemotherapy, for a difference of 7·8 (2·9 to 12·8; two-sided nominal p=0·0020). Fewer pembrolizumab-treated patients had deterioration in the QLQ-LC13 composite endpoint than did chemotherapy-treated patients (46 [31%] of 151 patients vs 58 [39%] of 148 patients). Time to deterioration was longer with pembrolizumab than with chemotherapy (median not reached [95% CI 8·5 to not reached] vs 5·0 months [3·6 to not reached]; hazard ratio 0·66, 95% CI 0·44-0·97; two-sided nominal p=0·029). INTERPRETATION: Pembrolizumab improves or maintains health-related QOL compared with that for chemotherapy, and might represent a new first-line standard of care for PD-L1-expressing, advanced NSCLC. FUNDING: Merck & Co.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Brahmer JR, Rodríguez-Abreu D, Robinson AG, et al. Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial. Lancet Oncol. 2017. PMID: 29129441. doi:10.1016/S1470-2045(17)30690-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。